Here is one outlook for marketing biosimilars. The main point of launching biosimilars is to subsidize costs of biologic drugs to patients and payers. It costs less to develop them; therefore, it would seem counterintuitive to spend the amount of money it takes for marketing, especially direct-to-consumer (DTC).
This article points out some more cost-effective options for pharma companies marketing biosimilars, which also happen to be specialties of ours at Aegis Creative, such as: educational training and resources for physicians and providers, and more digital approaches to providing information and education.
Read the full article at: www.fiercepharma.com